Biomarkers of Aging: From Function to Molecular Biology

Karl-Heinz Wagner 1,2,*, David Cameron-Smith 3, Barbara Wessner 1,4 and Bernhard Franzke 1

1 Research Platform Active Ageing, University of Vienna, Althanstrasse 14, Vienna 1090, Austria; barbara.wessner@univie.ac.at (B.W.); bernhard.franzke@univie.ac.at (B.F.)
2 Department of Nutritional Sciences, Faculty of Life Sciences, University of Vienna, Althanstrasse 14, Vienna 1090, Austria
3 Liggins Institute, University of Auckland, Private Bag 92019, Auckland 1142, New Zealand; d.cameron-smith@auckland.ac.nz
4 Department of Sport and Exercise Physiology, Centre for Sport Science and University Sports, University of Vienna, Auf der Schmelz 6, Vienna 1150, Austria

* Correspondence: karl-heinz.wagner@univie.ac.at; Tel.: +43-1-4277-54930

Received: 6 April 2016; Accepted: 30 May 2016; Published: 2 June 2016

Abstract: Aging is a major risk factor for most chronic diseases and functional impairments. Within a homogeneous age sample there is a considerable variation in the extent of disease and functional impairment risk, revealing a need for valid biomarkers to aid in characterizing the complex aging processes. The identification of biomarkers is further complicated by the diversity of biological living situations, lifestyle activities and medical treatments. Thus, there has been no identification of a single biomarker or gold standard tool that can monitor successful or healthy aging. Within this short review the current knowledge of putative biomarkers is presented, focusing on their application to the major physiological mechanisms affected by the aging process including physical capability, nutritional status, body composition, endocrine and immune function. This review emphasizes molecular and DNA-based biomarkers, as well as recent advances in other biomarkers such as microRNAs, bilirubin or advanced glycation end products.

Keywords: aging; biomarker; physical function; inflammaging; DNA based marker; molecular marker; miRNA

1. Introduction

Aging is a natural and multi-factorial phenomenon characterized by the accumulation of degenerative processes that are in turn underpinned by multiple alterations and damage within molecular pathways. The alterations and damage ultimately compromise cell and tissue functions [1,2]. As such, aging is the most profound risk factor for almost all non-communicable diseases, including cardiovascular diseases, cancer, diabetes and neurological diseases. The proposed mechanisms that contribute to the aging process and the development of these chronic, age-associated diseases include DNA damage, alterations in gene and non-coding RNA expression, genotoxicity, oxidative stress, and the incidence of shorter telomeres [3–5]. Despite the many theories that have been proposed to explain the phenomenon of aging, as yet none has been able to fully explain the mechanisms that drive the fundamental process(es) of aging [6]. Indeed, the understanding of aging has increased markedly, with current knowledge highlighting the importance of “network” theories of aging [7]. Based on these integrative theories, aging is best described as a multi-factorial process involving complex interactions between biological and molecular mechanisms [6,8–10]. Given this, it is unlikely that any single or readily defined set of biomarkers will provide a valid measure of biological aging.
However, it remains an important goal to provide increasingly accurate measures or predictors of the onset of ill health. Conversely, and of equal importance, is the ability to characterize the maintenance of age-appropriate optimal health. The ability to distinguish between what is normal biological aging and when health is adversely compromised is an important area for which little experimental data exists. As such, there is no gold standard tool for assessing healthy aging and no single measure has yet qualified as a sensitive and specific biomarker of aging. This results in some panels of markers that are associated with survival, health at old age, frailty, age-related (multi-) morbidity or disability. More recent attempts have aimed to statistically link multiple biomarkers that operate in different physiological networks using techniques such as principal component analysis to generate a more comprehensive insight of age-related health [11,12]. These strategies, when combined with recently identified molecular and DNA based markers, have the future potential to improve the prediction of healthy aging [3,13,14]. Thus, this short review will summarize a selected panel of the most promising biomarkers of healthy aging in humans (see Table 1). The definition of a biomarker for aging follows the guidelines of the American Federation of Aging Research [15].

Table 1. Summary of putative biomarkers of aging.

| Physical Function and Anthropometry | Practicability of Measurement | Outcome Prediction |
|-------------------------------------|------------------------------|--------------------|
| Walking speed                       | High                         | Mortality          |
| Chair stand                         | High                         | Mortality          |
| Standing balance                    | High                         | Mortality          |
| Grip strength                       | High                         | CVD                |
| Body Mass Index                     | High                         | CVD                |
| Waist circumference                 | High                         | CVD                |
| Muscle mass                         | High                         | Mortality          |

| Blood-based candidate markers       | Practicability of measurement | Outcome prediction                                      |
|-------------------------------------|------------------------------|---------------------------------------------------------|
| Inflammation IL-6, TNF-a, CRP       | moderate to high              | Mortality, grip strength                                |
| Network analysis of inflammatory markers | moderate               | Mortality                                               |
| Glucose metabolism: HbA1c, plasma glucose | moderate               | Mortality/CVD                                          |
| Adipokines                          | moderate                     | Mortality (moderate prediction) Ageing/frailty          |
| Thyroid hormones                    | moderate                     | Mortality/morbidity (moderate prediction)               |
| Vitamin D                           | low                          | CVD/Mortality/multimorbidity (Cognitive impairment)     |
| NT-proBNP Tropionin                 | moderate                     | Mortality/multimorbidity (Cognitive impairment)         |

| Molecular/DNA based markers         | Practicability of measurement | Outcome prediction                                      |
|-------------------------------------|------------------------------|---------------------------------------------------------|
| DNA/chromosomal damage              | low                          | Aging (moderate prediction)                             |
| Telomere length                     | low                          | Mortality (moderate prediction)                         |
| DNA repair                          | low                          | -                                                       |

| Novel markers                       | Practicability of measurement | Outcome prediction                                      |
|-------------------------------------|------------------------------|---------------------------------------------------------|
| Bilirubin (mainly unconjugated bilirubin) | moderate to high              | CVD, CVD-related mortality                              |
| Advanced glycation end products     | low                          | CVD                                                     |
| Metallothioneins                    | low                          | Aging brain                                             |
| DNA methylation                     | low                          | -                                                       |
| MicroRNAs                           | low                          | CVD aging (moderate prediction)                         |

2. Physical Function and Anthropometry

Measures of physical capability remain important markers of current and future health. Objective and standardized tests of physical capability have been developed and increasingly used in population-based studies. Functional assessments for physical performance such as handgrip strength, chair stand, gait speed, timed up and go, and six-minute walk tests are frequently used for monitoring the biological aging process. A weaker grip strength, slower walking speed, less repetitions in chair stand test, and poorer standing balance performance are all associated with significantly greater
mortality rates, independent of age in older community-dwelling populations. These findings have now been further confirmed with meta-analyses highlighting the strength of the association between slower walking speed and increased mortality rates [16,17]. More recent studies indicate that, in addition to grip strength and walking speed, standing balance and chair rise speed in middle-age predict mortality rates over 13 years of follow-up [18]. A weaker grip strength was also found to be associated with functional decline as assessed by self-reported difficulties performing activities of daily living (ADLs) [19].

Various studies and systematic reviews evaluating the risk for subsequent disability (by assessing ADLs) showed that older adults performing poorly in tests of physical capability are more likely to become functionally disabled [20,21]. There is also some evidence that poorer performance in grip strength, walking speed, strength of lower extremities and standing balance is associated with a higher risk for cardiovascular disease (CVD), dementia and institutionalization (as a marker for the loss of independence). In the UK Newcastle 85+ study, low handgrip strength was associated with multi-morbidity, cognitive impairment and disability [22]. Independent from the association with physical capacity, there is a significant decline in many aspects of cognitive functioning with aging, including memory processing, attention and visuo-spatial abilities, whereas some other aspects of cognitive functioning, such as vocabulary, may increase with age [23]. However, cognitive dysfunction is associated with higher risk of mortality in patients regardless of the underlying diagnosis. In this respect it has been shown that a score below 25 in the Mini-Mental State Examination is associated with the highest mortality rate [24].

Aging is also associated with body composition changes including increased body fat, reduced muscle mass, and reduced organ mass (with the exception of the heart). Higher abdominal adiposity is a risk factor for aging and for age-related diseases with the lowest mortality risk for those with waist circumferences below 94 cm for Caucasian men and 77 cm for Caucasian women. The relative risk of mortality is doubled for those with waist circumferences above 132 and 116 cm in men and women, respectively [25]. The body mass index (BMI) is a useful measure of overall adiposity since each 5 kg/m$^2$ increase in BMI is associated with a 30% higher overall mortality, a 40% higher vascular mortality, and a 60%–120% higher diabetic, renal, and hepatic mortality [26]. In addition, high BMI, independent of gender and other confounding factors, is a risk factor for cognitive decline [27].

Irrespective of the definition of sarcopenia, the age-related loss of skeletal muscle mass and strength [28,29], both low muscle mass and poor muscle function are highly prevalent and important risk factors for disability and mortality in aging [30,31]. Cross-sectional and prospective studies examining the relationship between regional muscle mass and health outcomes consistently reported that a low skeletal muscle index (skeletal muscle mass/body mass expressed as percentage) is associated with an increased likelihood of functional impairment and disability [32,33].

Collectively these studies all continue to point towards the importance of physical measures, including mobility and body composition as important biomarkers of aging. Further refinement will be required, as newer imaging methodologies become commonly applied, including magnetic resonance imaging (MRI) and peripheral quantitative computer tomography for the measurement of body composition and muscle mass with improved precision. Future technologies including wearable devices will increasingly provide accurate and real-time data on movement patterns, distinguishing the onset and severity of age-related ill health.

3. Blood-Based Candidate Biomarkers

Most aging biomarkers measured within blood samples are related to cardiovascular function, glucose metabolism, inflammation, nutritional status, endocrinology and simply hematology. Although there are many less well understood inflammation- and hemostasis-related biomarkers of cardiovascular function, the classical, widely measured, and well-documented physiological markers of risk of cardiovascular-related diseases remain some of the strongest biomarkers of aging [34]. Systematic reviews and meta-analyses provide strong evidence that the lipid profile (including
Nutrients 2016, 8, 338

Total cholesterol, low- and high-density lipoprotein cholesterol, and triglyceride concentrations) are predictors of morbidity and mortality [35–38].

Amongst the best studied aspects of immunosenescence is the age-related increase in inflammatory peptide biomarkers (interleukin (IL)-6, IL-1β, tumor necrosis factor-α (TNF-α) and C-reactive protein (CRP)), collectively termed “inflammaging” [39]. Higher plasma concentrations of inflammatory factors such as IL-6 and TNF-α have been associated with lower grip strength and gait speed in older adults, demonstrating the interconnection between immune and functional status in the elderly [40]. CRP has been related to all-cause and specific causes of mortality and IL-6 was found to be a strong predictor of mortality [41–43].

Measurement of inflammatory markers has been conducted in centenarians. Centenarians demonstrate fewer signs of inflammaging [11,12]. Whilst inflammatory peptides are either absent or lowered than that evident in younger cohorts, there is a corresponding increase in the levels of anti-inflammatory cytokines, such as IL-10 [44]. Importantly, much yet is to be understood with respect to the interactions between cytokines, the immune system and target organs. It is apparent that these inflammatory markers have many non-classical functions, including the modulation of metabolic functions, well beyond the classically described impact on inflammatory function.

Aging is associated with alterations in many aspects of metabolic and hormonal function, including altered expression of cellular insulin receptors and glucose transporter units in target tissues. Within these tissues there is corresponding changes in carbohydrate metabolism including decreased cellular glucose oxidation. These alterations result in a lowered glucose tolerance as measured by impaired ability to lower blood glucose after a standard glucose load. There are several measures of glucose tolerance with the clinically accepted measures for diagnosis of diabetes mellitus being the fasting and postprandial blood glucose concentration. Glycated hemoglobin, a measure of usual glucose concentrations over the preceding few months, which does not require fasting or a glucose challenge, has also been suggested as a feasible indicator of glucose metabolism [45].

Recently it was shown that markers related to red blood cells, more specifically hematocrit, hemoglobin and the red blood cell count are associated with significantly higher chances of adverse health-status measures such as multi-morbidity, cognitive impairment, disability and mortality [22]. Age-related changes in the endocrine system are very well established including a decline in the sex hormones estrogen and testosterone due to menopause and andropause and the reduced production of growth hormone and insulin-like growth factor-1 (somatopause) [46–48].

The more recently discovered adipokines such as adiponectin, ghrelin, leptin and visfatin are key regulators of inflammation as well as of central functions such as appetite regulation. Alterations in serum adipokine levels have been linked with an increased risk of obesity and metabolic syndrome [49]. Interestingly, the concentration of adiponectin appears to change with age and is linked with age-related health outcomes, however further research on the association between aging and adipokines is required [50].

Other hormonal changes including thyroid-stimulating hormone (TSH), free thyroxine (FT4) and triiodothyronine (FT3) have also been evaluated on their link to health outcomes in elderly, but only low FT3 levels were associated with an increased risk for morbidity and mortality [22]. These findings are consistent with other studies investigating aged populations, showing an association of low serum FT3 with reduced parameters of physical performance and muscle strength [51], as well as an increased disease-burden and mortality [51,52].

Nutrition-related parameters are diverse, although studies have tended to focus primarily on a small subset of micronutrients including the vitamins D, B12, B6 and folic acid. However, data are not convincing, with limited evidence that suppressed vitamin D levels are associated with increased overall morbidity and cognitive impairment [22,53].

Other very interesting aging markers are N-terminal pro-B-type natriuretic peptide (NT-proBNP) and cardiac troponin, both of which are highly linked to myocardial damage. Recently it has been shown that NT-proBNP, which is elevated in the presence of heart failure, is associated
with multi-morbidity, cognitive impairment and mortality [22,54], which makes NT-proBNP an informative general marker of age-related myocardial dysfunction. Cardiac troponin is associated with physiological renewal or remodeling of the myocardium. It is significantly correlated to NT-proBNP [55,56]. Despite their validity as predictors for cardiac damage and cardiovascular diseases, both markers increase with age, importantly until very old age, in both male and female healthy subjects, which successfully qualifies them as biomarkers for human aging [22,57].

Despite the apparent relevance of many of these blood-borne measures longitudinal data to precisely identify the predictive value of these markers prior to the onset of ill health are scarce. There is, however, substantial evidence that the timely analysis of blood borne biomarkers should be a common feature of geriatric care, with the need to establish normative standards and appropriate age-related reference ranges.

4. Molecular/DNA-Based Markers—Are They Good Aging Predictors?

Common theories of aging, where age linearly correlates with and/or is caused by the accumulation of reactive oxygen species (ROS), DNA damage, mitochondrial dysfunction, impaired antioxidant defense and shortening of the telomeres [58], are well established in humans. However it has been reported that many of these markers increase up to a certain age, most commonly coinciding with the statistical life-expectancy. Thereafter, a plateau or even a decrease in the level of some of these biomarkers has been described.

Supported by the free radical theory of aging, it is widely accepted that the production of ROS by mitochondria accumulates over the lifespan leads to a state of chronic oxidative stress at old age. As antioxidant defense mechanisms and DNA repair capacity seem to be impaired in the elderly, DNA damage has been proposed to be a consequence of aging [59]. Impaired DNA stability increases the frequency of cytogenetic aberrations, which in turn is highly linked to age-related diseases such as cancer, diabetes, cardiovascular diseases and cognitive decline [60,61]. However, after linearly increasing until the age of 60–70 years [62,63], chromosomal damage tapers and the rate of damage diminished with increasing age (over 85 years) [64]. Notably, the same seems to be true for telomeres, the protective ends of the chromosomes [65]. Longer telomeres and higher telomerase activity contribute to the stability of the genome, to DNA integrity and are positively correlated with the aging process [66].

Both, the “regular” aging process and the development of chronic diseases are accompanied by increased DNA damage, chromosomal damage, and telomere shortening [59,60,63,67]. Importantly, people exceeding the statistical life-expectancy, and especially the very oldest age-groups including nonagenarians (90–99 years), centenarians (100–109 years) and super-centenarians (110 years and older), demonstrate a different picture of age-related diseases compared to study cohorts at or below life-expectancy [68]. Furthermore, an increasing amount of data suggests that chromosomal stability, DNA repair activity, and antioxidant defense capacity in successfully aged subjects is comparable to younger cohorts [3,69,70].

Taken together, very old humans seem to contradict traditional theories of aging regarding the age-related accumulation of DNA damage, genome instability and telomere shortening by demonstrating better DNA repair capacity and higher telomerase activity, even comparable to much younger cohorts. Whether the superior resilience of “successful” agers originates from hereditary factors or an outstanding healthy lifestyle remains a field for future research. Conclusively, markers of DNA integrity, genome stability, antioxidant defense or telomere length based on current evidence do not meet the criteria for a valid biomarker for aging.

5. Novel and Not-Established Markers

Bilirubin, the principal tetrapyrrole, bile pigment and catabolite of haem, is an emerging biomarker to monitor resistance against chronic non-communicable diseases. Mildly elevated serum bilirubin levels have been reported to be strongly associated with reduced CVD-related mortality and associated
risk factors. Recent data also link bilirubin to all-cause mortality and to other chronic diseases, including cancer and type 2 diabetes mellitus. Therefore, there is evidence to suggest bilirubin as a biomarker for reduced chronic disease prevalence and for the prediction of all-cause mortality, but also as a novel biomarker for successful aging [71,72].

Advanced glycation end products (AGEs) represent further biomarkers with some potential to monitor healthy aging. Protein modifications such as the non-enzymatic protein glycation are common posttranslational modification of proteins resulting from reactions between glucose and the amino groups of proteins. This process, better known as ‘Maillard reaction’, leads to the formation of AGEs. Interestingly, the AGEs of long-lived proteins such as collagens and cartilage accumulate during normal aging. They are involved either directly or through interactions with the AGE-receptors in the pathophysiology of numerous age-related diseases including CVD, renal disease and neurodegeneration [73].

Metallothioneins (MTs) are low molecular weight, cysteine rich, zinc-binding proteins, which are down-regulated in older age groups [74]. MTs exert an essential role in zinc-mediated transcriptional regulation of genes involved in growth, proliferation, differentiation, and development, pathways of importance in neural function. There is experimental evidence that MTs are induced in the aging brain as a defensive mechanism to attenuate oxidative and nitrative stress. MTs may also act as free radical scavengers by inhibiting Charnoly body formation, thus contributing to protecting mitochondrial function as a mechanism of neuroprotection in the aging brain [75].

Very recently the interesting model of the “epigenetic clock” has been advanced with the analysis of peripheral blood mononuclear cells isolated from semi-supercentenarians and their offspring [76,77]. The epigenetic clock is a multivariate estimator of chronological age based on DNA methylation levels of 353 dinucleotide markers known as Cytosine phosphate Guanines (CpGs). Extent and patterns of CpGs are independently associated with chronological age and mortality [78]. Further data is required to understand whether these changes are correlative or causal in the maintenance of health with advancing age.

Epigenetic changes are but one of a number of emerging molecular markers of altered molecular function in aging that may be predictive of health status. Recent studies have examined the novel molecular marker p16^{INK4a}, which is classically known for its capacity to inhibit cyclin-dependent kinase activity. Long-term p16^{INK4a} expression is a promoter of cellular senescence, a process of irreversible cell-cycle arrest and the loss of regenerative capacity. Therefore, precise regulation of p16^{INK4a} is essential to tissue homeostasis, maintaining a coordinated balance between tumor suppression and aging [79]. As yet, studies in human populations and differing cell types have yet to be conducted to provide evidence of its potential as a biomarker of healthy aging.

Finally, microRNAs (miRNAs), single-stranded and non-coding RNA molecules of 21–23 nucleotides that regulate a broad spectrum of biological activities, have been proposed as signatures of aging [80]. These small RNA molecules were initially demonstrated to contribute to aging of C. elegans and show differential expression levels in tissues of young and old animal models [81,82]. Most interestingly miRNAs are stable molecules even in serum and/or plasma, hence are regarded as promising markers in the clinical setting [83]. Of the many miRNAs expressed in the human genome, potential candidate analysis is focused on miR-146, miR-155, miR-21 and miR-126 [84–86]. These studies have been extended to demonstrate a specificity of age-related health loss, with the ability to differentiate the onset of Alzheimer’s disease and/or mild cognitive impairment from cognitively normal age-matched controls with some degree of accuracy utilizing a miRNA signature analysis [87]. Furthermore, miRNAs might also serve as circulating biomarkers for cardiovascular aging or aging-associated diseases [88], but further research needs to be conducted to evaluate their sensitivity, selectivity and potential as predictive biomarkers for discriminating successful from non-successful aging.
6. Conclusions

Due to the complexity of the many biological and molecular mechanisms of aging, no single biomarker will provide a valid measure of healthy aging. Based on the available evidence, there is yet to emerge any newly identified measures of molecular function that out-perform the existing lipid, peptide and hormonal biomarkers routinely analyzed in blood. Often overlooked is the value of combining such measures with the well-established markers of physical and functional parameters.

Currently many novel markers are under evaluation, made possible with new analysis technologies or greater insights into the fundamental molecular basis of the loss of functionality and onset of dysfunction at the cellular level. Thus the number of potential candidates is anticipated to grow markedly. The so-called “omics” techniques such as metabolomics, proteomics or genomics will further trigger data generation and might offer the opportunity for an unbiased systematic discovery route for novel biomarkers of aging. However, verification against health measurements will take some time [14]. It remains to be elucidated which markers will achieve the status as reliable predictors of biological aging and provide a measure of ongoing optimal health.

Acknowledgments: This review was conducted within the Research Platform “Active Ageing“ and the EU-IRSES-318962—BIOAGE project.

Author Contributions: K.H.W. and B.F. were responsible for the conception of the review and drafted the initial manuscript. B.W. and D.C.S. revised it critically for intellectual content. All authors gave the final approval for the final article.

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations

The following abbreviations are used in this manuscript:

- AGEs: Advanced glycation end products
- ADLs: Activities of daily living
- BMI: Body mass index
- CRP: C-reactive protein
- CVD: Cardiovascular disease
- FT3: free triiodothyronine
- FT4: free thyroxin
- IL: Interleukin
- miRNA: microRNA
- MRI: Magnetic resonance imaging
- MTs: Metallothioneins
- NT-pro-BNP: N-terminal pro-B-type natriuretic peptide
- ROS: Reactive oxygen species
- TNF-α: Tumor necrosis factor-α
- TSH: Thyroid-stimulating hormone

References

1. Bratic, A.; Larsson, N.G. The role of mitochondria in aging. *J. Clin. Investig.* 2013, 123, 951–957. [CrossRef] [PubMed]
2. Kirkwood, T.B. Understanding the odd science of aging. *Cell* 2005, 120, 437–447. [CrossRef] [PubMed]
3. Franzke, B.; Neubauer, O.; Wagner, K.H. Super dnaging-new insights into DNA integrity, genome stability and telomeres in the oldest old. *Mutat. Res. Rev. Mutat. Res.* 2015, 766, 48–57. [CrossRef] [PubMed]
4. Lovell, M.A.; Markesbery, W.R. Oxidative DNA damage in mild cognitive impairment and late-stage Alzheimer’s disease. *Nucleic Acids Res.* 2007, 35, 7497–7504. [CrossRef] [PubMed]
5. Martin-Ruiz, C.; Dickinson, H.O.; Keys, B.; Rowan, E.; Kenny, R.A.; von Zglinicki, T. Telomere length predicts poststroke mortality, dementia, and cognitive decline. *Ann. Neurol.* 2006, 60, 174–180. [CrossRef] [PubMed]
6. Slijepcevic, P. DNA damage response, telomere maintenance and ageing in light of the integrative model. *Mech. Ageing Dev.* **2008**, *129*, 11–16. [CrossRef] [PubMed]

7. Weinert, B.T.; Timiras, P.S. Invited review: Theories of aging. *J. Appl. Physiol.* **2003**, *95*, 1706–1716. [CrossRef] [PubMed]

8. Kirkwood, T.B.; Kowald, A. Network theory of aging. *Exp. Gerontol.* **1997**, *32*, 395–399. [CrossRef]

9. Borup, M.T.; Trusina, A.; Andersson, A.M. Aging mechanism as the “down side” of adaptation: A network approach. *J. Theor. Biol.* **2008**, *250*, 66–74. [CrossRef] [PubMed]

10. Von Zglinicki, T.; Burkle, A.; Kirkwood, T.B. Stress, DNA damage and ageing—An integrative approach. *Exp. Gerontol.* **2001**, *36*, 1049–1062. [CrossRef]

11. Cohen, A.A.; Milot, E.; Li, Q.; Bergeron, P.; Poirier, R.; Dusseauelt-Belanger, F.; Fulp, T.; Leroux, M.; Legault, V.; Metter, E.J.; *et al.* Detection of a novel, integrative aging process suggests complex physiological integration. *PLoS ONE* **2015**, *10*, e0116489. [CrossRef] [PubMed]

12. Arai, Y.; Martin-Ruiz, C.M.; Takayama, M.; Abe, Y.; Takebayashi, T.; Koyasu, S.; Suematsu, M.; Hirose, N.; von Zglinicki, T. Inflammation, but not telomere length, predicts successful ageing at extreme old age: A longitudinal study of semi-supercentenarians. *EBioMedicine* **2015**, *2*, 1549–1558. [CrossRef] [PubMed]

13. Hatse, S.; Brouwers, B.; Dalmasso, B.; Laenen, A.; Kenis, C.; Schoffski, P.; Wildiers, H. Circulating micronas as easy-to-measure aging biomarkers in older breast cancer patients: Correlation with chronological age but not with fitness/frailty status. *PLoS ONE* **2014**, *9*, e101644.

14. Burkle, A.; Moreno-Villanueva, M.; Bernhard, J.; Blasco, M.; Zondag, G.; Hoeijmakers, J.H.; Toussaint, O.; von Zglinicki, T. Inflammation, but not telomere length, predicts successful ageing at extreme old age: A longitudinal study of semi-supercentenarians. *EBioMedicine* **2015**, *2*, 1549–1558. [CrossRef] [PubMed]

15. Cooper, R.; Kuh, D.; Hardy, R. Mortality Review Group; FALCon and HALCyon Study Teams. Objectively measured physical capability levels and mortality: Systematic review and meta-analysis. *BMJ* **2010**, *341*, c4467. [CrossRef] [PubMed]

16. Ruff, R.M.; Parker, S.B. Gender- and age-specific changes in motor speed and eye-hand coordination in adults: Normative values for the finger tapping and grooved pegboard tests. *Percept. Mot. Skills* **1993**, *76*, 1219–1230. [CrossRef] [PubMed]

17. Johnson, T.E. Recent results: Biomarkers of aging. *Exp. Gerontol.* **2006**, *41*, 1243–1246. [CrossRef] [PubMed]

18. Studenski, S.; Perera, S.; Patel, K.; Rosano, C.; Faulkner, K.; Inzitari, M.; Brach, J.; Chandler, J.; Cathnon, P.; O’Connor, E.B.; *et al.* Gait speed and survival in older adults. *JAMA* **2011**, *305*, 50–58. [CrossRef] [PubMed]

19. Cooper, R.; Kuh, D.; Hardy, R. Mortality Review Group; FALCon and HALCyon Study Teams. Objectively measured physical capability levels and mortality: Systematic review and meta-analysis. *BMJ* **2010**, *341*, c4467. [CrossRef] [PubMed]

20. Vermeulen, J.; Neyens, J.C.; van Rossum, E.; Spreeuwenberg, M.D.; de Witte, L.P. Predicting adl disability in community-dwelling elderly people using physical frailty indicators: A systematic review. *Mech. Ageing Dev.* **2011**, *132*, 11–33. [CrossRef] [PubMed]

21. Gobens, R.J.; van Assen, M.A.; Schalk, M.J. The prediction of disability by self-reported physical frailty components of the tilburg frailty indicator (tfi). *Arch. Gerontol. Geriatr.* **2014**, *59*, 280–287. [CrossRef] [PubMed]

22. Martin-Ruiz, C.; Jagger, C.; Kingston, A.; Collerton, J.; Catt, M.; Davies, K.; Dunn, M.; Hilkens, C.; Keavney, B.; Pearce, S.H.; *et al.* Assessment of a large panel of candidate biomarkers of ageing in the newcastle 85+ study. *Mech. Ageing Dev.* **2011**, *132*, 496–502. [CrossRef] [PubMed]

23. Salthouse, T.A. Selective review of cognitive aging. *J. Int. Neuropsychol. Soc.* **2010**, *16*, 754–760. [CrossRef] [PubMed]

24. Su, Y.P.; Chang, C.K.; Hayes, R.D.; Perera, G.; Broadbent, M.; To, D.; Hotopf, M.; Stewart, R. Mini-mental state examination as a predictor of mortality among older people referred to secondary mental healthcare. *PLoS ONE* **2014**, *9*, e105312. [CrossRef] [PubMed]

25. De Hollander, E.L.; Bemelmans, W.J.; Bosshuizen, H.C.; Friedrich, N.; Wallaschowski, H.; Guillard-Castillon, P.; Walter, S.; Zillikens, M.C.; Rosengren, A.; Lissner, L.; *et al.* The association between waist circumference and risk of mortality considering body mass index in 65- to 74-year-olds: A meta-analysis of 29 cohorts involving more than 58,000 elderly persons. *Int. J. Epidemiol.* **2012**, *41*, 805–817. [CrossRef] [PubMed]
26. Prospective Studies Collaboration; Whitlock, G.; Lewington, S.; Sherliker, P.; Clarke, R.; Emberson, J.; Halsey, J.; Qizilbash, N.; Collins, R.; Peto, R. Body-mass index and cause-specific mortality in 900,000 adults: Collaborative analyses of 57 prospective studies. *Lancet* **2009**, *373*, 1083–1096. [PubMed]

27. Gallucci, M.; Mazzuco, S.; Ongaro, F.; di Giorgi, E.; Mecocci, P.; Cesari, M.; Albani, D.; Forloni, G.L.; Durante, E.; Gago, G.B.; et al. Body mass index, lifestyles, physical performance and cognitive decline: The “treviso longeva (trelong)” study. *J. Nutr. Health Aging* **2013**, *17*, 378–384. [CrossRef] [PubMed]

28. Cruz-Jentoft, A.J.; Baeyens, J.P.; Bauer, J.M.; Boirie, Y.; Cederholm, T.; Landi, F.; Martin, F.C.; Michel, J.P.; Rolland, Y.; Schneider, S.M.; et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European working group on sarcopenia in older people. *Age Ageing* **2010**, *39*, 412–423. [CrossRef] [PubMed]

29. Cesari, M.; Fielding, R.A.; Pahor, M.; Goodpaster, B.; Hellerstein, M.; van Kan, G.A.; Anker, S.D.; Rutkove, S.; Vrijbloom, J.W.; Isaac, M.; et al. Biomarkers of sarcopenia in clinical trials-recommendations from the international working group on sarcopenia. *J. Cachexia Sarcopenia Muscle* **2012**, *3*, 181–190. [CrossRef] [PubMed]

30. Goodpaster, B.H.; Park, S.W.; Harris, T.B.; Kritchevsky, S.B.; Nevitt, M.; Schwartz, A.V.; Simonsick, E.M.; Tylavsky, F.A.; Visser, M.; Newman, A.B. The loss of skeletal muscle strength, mass, and quality in older adults: The health, aging and body composition study. *J. Gerontol. A Biol. Sci. Med. Sci.* **2006**, *61*, 1059–1064. [CrossRef] [PubMed]

31. Visser, M.; Pahor, M.; Tylavsky, F.; Kritchevsky, S.B.; Cauley, J.A.; Newman, A.B.; Blunt, B.A.; Harris, T.B. One- and two-year change in body composition as measured by dxa in a population-based cohort of older men and women. *J. Appl. Physiol.* **2003**, *94*, 2368–2374. [CrossRef] [PubMed]

32. Koster, A.; Ding, J.; Stenholm, S.; Caserotti, P.; Houston, D.K.; Nicklas, B.J.; You, T.; Lee, J.S.; Visser, M.; Newman, A.B.; et al. Does the amount of fat mass predict age-related loss of lean mass, muscle strength, and muscle quality in older adults? *J. Gerontol. A Biol. Sci. Med. Sci.* **2011**, *66*, 888–895. [CrossRef] [PubMed]

33. Janssen, I.; Heymsfield, S.B.; Ross, R. Low relative skeletal muscle mass (sarcopenia) in older persons is associated with functional impairment and physical disability. *J. Am. Geriatr. Soc.* **2002**, *50*, 889–896. [CrossRef] [PubMed]

34. Vlachopoulos, C.; Xaplanteris, P.; Aboyans, V.; Brodman, M.; Cifkova, R.; Cosentino, F.; de Carlo, M.; Gallino, A.; Landmesser, U.; Laurent, S.; et al. The role of vascular biomarkers for primary and secondary prevention. A position paper from the European society of cardiology working group on peripheral circulation: Endorsed by the association for research into arterial structure and physiology (artery) society. *Atherosclerosis* **2015**, *241*, 507–532. [PubMed]

35. Lewington, S.; Clarke, R.; Qizilbash, N.; Peto, R.; Collins, R.; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. *Lancet* **2002**, *360*, 1903–1913. [CrossRef]

36. Prospective Studies Collaboration; Lewington, S.; Whitlock, G.; Clarke, R.; Sherliker, P.; Emberson, J.; Halsey, J.; Qizilbash, N.; Peto, R.; Collins, R. Blood cholesterol and vascular mortality by age, sex, and blood pressure: A meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. *Lancet* **2007**, *370*, 1829–1839. [PubMed]

37. Briel, M.; Ferreira-Gonzalez, I.; You, J.J.; Karanicolis, P.J.; Akl, E.A.; Wu, P.; Blechacz, B.; Bassler, D.; Wei, X.; Sharman, A.; et al. Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: Systematic review and meta-regression analysis. *BMJ* **2009**, *338*, b92. [CrossRef] [PubMed]

38. Sarwar, N.; Danesh, J.; Eiriksdottir, G.; Sigurdsson, G.; Wareham, N.; Bingham, S.; Boekholdt, S.M.; Khaw, K.T.; Gudnason, V. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 western prospective studies. *Circulation* **2007**, *115*, 450–458. [CrossRef] [PubMed]

39. Franceschi, C.; Bonafe, M.; Valensin, S.; Oliveri, F.; de Luca, M.; Ottaviani, E.; de Benedictis, G. Inflamm-aging. An evolutionary perspective on immunosenescence. *Ann. N. Y. Acad. Sci.* **2000**, *908*, 244–254. [CrossRef] [PubMed]

40. Visser, M.; Pahor, M.; Taaffe, D.R.; Goodpaster, B.H.; Simonsick, E.M.; Newman, A.B.; Nevitt, M.; Harris, T.B. Relationship of interleukin-6 and tumor necrosis factor-alpha with muscle mass and muscle strength in elderly men and women: The health abc study. *J. Gerontol. A Biol. Sci. Med. Sci.* **2002**, *57*, M326–M332. [CrossRef] [PubMed]
41. Emerging Risk Factors Collaboration; Kaptoge, S.; di Angelantonio, E.; Lowe, G.; Pepys, M.B.; Thompson, S.G.; Collins, R.; Danesi, G. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: An individual participant meta-analysis. *Lancet* 2010, 375, 132–140. [PubMed]

42. Kabagambe, E.K.; Judd, S.E.; Howard, V.J.; Zakai, N.A.; Jenny, N.S.; Hsieh, M.; Warnock, D.G.; Cushman, M. Inflammation biomarkers and risk of all-cause mortality in the reasons for geographic and racial differences in stroke cohort. *Am. J. Epidemiol.* 2011, 174, 284–292. [CrossRef] [PubMed]

43. Lakoski, S.G.; Le, A.H.; Muntner, P.; Judd, S.E.; Safford, M.M.; Levine, D.A.; Howard, G.; Cushman, M. Adiposity, inflammation, and risk for death in black and white men and women in the United States: The reasons for geographic and racial differences in stroke (regards) study. *J. Clin. Endocrinol. Metab.* 2011, 96, 1805–1814. [CrossRef] [PubMed]

44. Salvioli, S.; Capri, M.; Bucci, L.; Lanni, C.; Racchi, M.; Uberti, D.; Memò, M.; Mari, D.; Govoni, S.; Franceschi, C. Why do centenarians escape or postpone cancer? The role of igf-1, inflammation and p53. *Cancer Immunol. Immunother.* 2009, 58, 1909–1917. [CrossRef] [PubMed]

45. International Expert Committee. International expert committee report on the role of the a1c assay in the diagnosis of diabetes. *Diabetes Care* 2009, 32, 1327–1334.

46. Lobo, R.A. Where are we 10 years after the women’s health initiative? *J. Clin. Endocrinol. Metab.* 2013, 98, 1771–1780. [CrossRef] [PubMed]

47. Cunningham, G.R. Andropause or male menopause? Rationale for testosterone replacement therapy in older men with low testosterone levels. *Endocr. Pract.* 2013, 19, 847–852. [CrossRef] [PubMed]

48. Junnila, R.K.; List, E.O.; Berryman, D.E.; Murrey, J.W.; Kopchick, J.J. The gh/igf-1 axis in ageing and longevity. *Nat. Rev. Endocrinol.* 2013, 9, 366–376. [CrossRef] [PubMed]

49. Ouchi, N.; Parker, J.L.; Lugus, J.J.; Walsh, K. Adipokines in inflammation and metabolic disease. *Nat. Rev. Immunol.* 2011, 11, 85–97. [CrossRef] [PubMed]

50. Poehls, J.; Wassel, C.L.; Harris, T.B.; Havel, P.J.; Swarbrick, M.M.; Newman, A.B.; Satterfield, S.; Kanaya, A.M. Association of adiponectin with mortality in older adults: The health, aging, and body composition study. *Diabetologia* 2009, 52, 591–595. [CrossRef] [PubMed]

51. Van den Beld, A.W.; Visser, T.J.; Feelders, R.A.; Grobbee, D.E.; Lambert, S.W. Thyroid hormone concentrations, disease, physical function, and mortality in elderly men. *J. Clin. Endocrinol. Metab.* 2005, 90, 6403–6409. [CrossRef] [PubMed]

52. Forestier, E.; Vinzio, S.; Sapin, R.; Schlienger, J.L.; Goichot, B. Increased reverse triiodothyronine is associated with shorter survival in independently-living elderly: The alsanut study. *Eur. J. Endocrinol.* 2009, 160, 207–214. [CrossRef] [PubMed]

53. Llewellyn, D.J.; Lang, L.A.; Langa, K.M.; Muniz-Terrera, G.; Phillips, C.L.; Cherubini, A.; Ferrucci, L.; Melzer, D. Vitamin D and risk of cognitive decline in elderly persons. *Arch. Intern. Med.* 2010, 170, 1135–1141. [CrossRef] [PubMed]

54. Kistorp, C.; Raymond, I.; Pedersen, F.; Gustafsson, F.; Faber, J.; Hildebrandt, P. N-terminal pro-brain natriuretic peptide, c-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. *JAMA* 2005, 293, 1609–1616. [CrossRef] [PubMed]

55. Frassl, W.; Kowoll, R.; Katz, N.; Speth, M.; Stangl, A.; Brechtel, L.; Joscht, B.; Boldt, L.H.; Meier-Buttermilch, R.; Schlemmer, M.; et al. Cardiac markers (bnp, nt-pro-bnp, troponin I, troponin T, in female amateur runners before and up until three days after a marathon. *Clin. Lab.* 2008, 54, 81–87. [PubMed]

56. Giannoni, A.; Giovannini, S.; Clerico, A. Measurement of circulating concentrations of cardiac troponin I and T in healthy subjects: A tool for monitoring myocardial tissue renewal? *Clin. Chem. Lab. Med.* 2009, 47, 1167–1177. [CrossRef] [PubMed]

57. Clerico, A.; Fortunato, A.; Ripoli, A.; Prontera, C.; Zucchelli, G.C.; Emdin, M. Distribution of plasma cardiac troponin I values in healthy subjects: Pathophysiological considerations. *Clin. Chem. Lab. Med.* 2008, 46, 804–808. [CrossRef] [PubMed]

58. Park, D.C.; Yeo, S.G. Aging. *Korean J. Audiol.* 2013, 17, 39–44. [CrossRef] [PubMed]

59. Hazane, F.; Sauvaigo, S.; Douki, T.; Favier, A.; Beani, J.C. Age-dependent DNA repair and cell cycle distribution of human skin fibroblasts in response to uva irradiation. *J. Photochem. Photobiol. B* 2006, 82, 214–223. [CrossRef] [PubMed]

60. Fenech, M. Important variables that influence base-line micronucleus frequency in cytokinesis-blocked lymphocytes—a biomarker for DNA damage in human populations. *Mutat. Res.* 1998, 404, 155–165. [CrossRef]
61. Mullner, E.; Brath, H.; Toferer, D.; Adrigan, S.; Bulla, M.T.; Stieglmayer, R.; Wallner, M.; Marek, R.; Wagner, K.H. Genome damage in peripheral blood lymphocytes of diabetic and non-diabetic individuals after intervention with vegetables and plant oil. *Mutagenesis* 2013, 28, 205–211. [CrossRef] [PubMed]

62. Fenech, M.; Bonassi, S. The effect of age, gender, diet and lifestyle on DNA damage measured using micronucleus frequency in human peripheral blood lymphocytes. *Mutagenesis* 2011, 26, 43–49. [CrossRef] [PubMed]

63. Wallner, M.; Blassnigg, S.M.; Marisch, K.; Pappenheim, M.T.; Mullner, E.; Molzer, C.; Nersesyan, A.; Marculescu, R.; Doberer, D.; Knasmuller, S.; et al. Effects of unconjugated bilirubin on chromosomal damage in individuals with Gilbert’s syndrome measured with the micronucleus cytome assay. *Mutagenesis* 2012, 27, 731–735. [CrossRef] [PubMed]

64. Franzke, B.; Halper, B.; Hofmann, M.; Oesen, S.; Peherstorfer, H.; Krejci, K.; Koller, B.; Geider, K.; Baiel, A.; Tosevska, A.; et al. The influence of age and aerobic fitness on chromosomal damage in Austrian institutionalised elderly. *Mutagenesis* 2014, 29, 441–445. [CrossRef] [PubMed]

65. Stewart, J.A.; Chaiken, M.F.; Wang, F.; Price, C.M. Maintaining the end: Roles of telomere proteins in end-protection, telomere replication and length regulation. *Mutat. Res.* 2012, 730, 12–19. [CrossRef] [PubMed]

66. Sanders, J.L.; Newman, A.B. Telomere length in epidemiology: A biomarker of aging, age-related disease, both, or neither? *Epidemiol. Rev.* 2013, 35, 112–131. [CrossRef] [PubMed]

67. Rodier, F.; Kim, S.H.; Nijjar, T.; Yaswen, P.; Campisi, J. Cancer and aging: The importance of telomeres in genome maintenance. *Int. J. Biochem. Cell Biol.* 2005, 37, 977–990. [CrossRef] [PubMed]

68. Garagnani, P.; Giuliani, C.; Pirazzini, C.; Olivieri, F.; Bacalini, M.G.; Ostan, R.; Mari, D.; Passarino, G.; Monti, D.; Bonfigli, A.R.; et al. Centenarians as super-controls to assess the biological relevance of genetic risk factors for common age-related diseases: A proof of principle on type 2 diabetes. *Aging* 2013, 5, 373–385. [CrossRef] [PubMed]

69. Tedone, E.; Arosio, B.; Gussago, C.; Casati, M.; Ferri, E.; Ogliari, G.; Ronchetti, F.; Porta, A.; Massariello, F.; Nicolini, P.; et al. Leukocyte telomere length and prevalence of age-related diseases in semisupercentenarians, centenarians and centenarians’ offspring. *Exp. Gerontol.* 2014, 58, 90–95. [CrossRef] [PubMed]

70. Chevanne, M.; Calia, C.; Zampieri, M.; Cecchinelli, B.; Caldini, R.; Monti, D.; Bucci, L.; Franceschi, C.; Caiafa, P. Oxidative DNA damage repair and parp 1 and parp 2 expression in Epstein-Barr virus-immortalized b lymphocyte cells from young subjects, old subjects, and centenarians. *Rejuvenation Res.* 2007, 10, 191–204. [CrossRef] [PubMed]

71. Wagner, K.H.; Wallner, M.; Molzer, C.; Gazzini, S.; Bulmer, A.C.; Tiribelli, C.; Vitek, L. Looking to the horizon: The role of bilirubin in the development and prevention of age-related chronic diseases. *Clin. Sci.* 2015, 129, 1–25. [CrossRef] [PubMed]

72. Wallner, M.; Marculescu, R.; Doberer, D.; Wolzt, M.; Wagner, O.; Vitek, L.; Bulmer, A.C.; Wagner, K.H. Protection from age-related increase in lipid biomarkers and inflammation contributes to cardiovascular protection in Gilbert’s syndrome. *Clin. Sci.* 2013, 125, 257–264. [CrossRef] [PubMed]

73. Simm, A.; Muller, B.; Nass, N.; Hofmann, B.; Bushnaq, H.; Silber, R.E.; Bartling, B. Protein glycation—Between tissue aging and protection. *Exp. Gerontol.* 2015, 68, 71–75. [CrossRef] [PubMed]

74. Malavolta, M.; Cipriano, C.; Costarelli, L.; Giaconii, R.; Tesei, S.; Muti, E.; Piacenza, F.; Pierpaoli, S.; Larbi, A.; Pawelec, G.; et al. Metallothionein downregulation in very old age: A phenomenon associated with cellular senescence? *Rejuvenation Res.* 2008, 11, 455–459. [CrossRef] [PubMed]

75. Sharma, S.; Rais, A.; Sandhu, R.; Nel, W.; Ebadi, M. Clinical significance of metallothioneins in cell therapy and nanomedicine. *Int. J. Nanomed.* 2013, 8, 1477–1488. [CrossRef] [PubMed]

76. Horvath, S.; Pirazzini, C.; Bacalini, M.G.; Gentilini, D.; di Blasio, A.M.; Delledonne, M.; Mari, D.; Arosio, B.; Monti, D.; Passarino, G.; et al. Decreased epigenetic age of pbmc from Italian semi-supercentenarians and their offspring. *Aging* 2015, 7, 1159–1170. [CrossRef] [PubMed]

77. Lowe, D.; Horvath, S.; Raj, K. Epigenetic clock analyses of cellular senescence and ageing. *Oncotarget* 2016, 7, 8524–8531. [PubMed]

78. Marioni, R.E.; Harris, S.E.; Shah, S.; McRae, A.F.; von Zglinicki, T.; Martin-Ruiz, C.; Wray, N.R.; Visscher, P.M.; Deary, I.J. The epigenetic clock and telomere length are independently associated with chronological age and mortality. *Int. J. Epidemiol.* 2016. [CrossRef] [PubMed]
79. LaPak, K.M.; Burd, C.E. The molecular balancing act of p16(ink4a) in cancer and aging. *Mol. Cancer Res.* 2014, 12, 167–183. [CrossRef] [PubMed]

80. Wessner, B.; Gryadunov-Masutti, L.; Tschan, H.; Bachl, N.; Roth, E. Is there a role for microRNAs in exercise immunology? A synopsis of current literature and future developments. *Exerc. Immunol. Rev.* 2010, 16, 22–39. [PubMed]

81. Ibanez-Ventoso, C.; Driscoll, M. MicroRNAs in *C. elegans* aging: Molecular insurance for robustness? *Curr. Genom.* 2009, 10, 144–153. [CrossRef] [PubMed]

82. Inukai, S.; Slack, F. MicroRNAs and the genetic network in aging. *J. Mol. Biol.* 2013, 425, 3601–3608. [CrossRef] [PubMed]

83. Keller, A.; Meese, E. Can circulating microRNAs live up to the promise of being minimal invasive biomarkers in clinical settings? *Wiley Interdiscip. Rev. RNA* 2016, 7, 148–156. [CrossRef] [PubMed]

84. McGregor, R.A.; Poppitt, S.D.; Cameron-Smith, D. Role of microRNAs in the age-related changes in skeletal muscle and diet or exercise interventions to promote healthy aging in humans. *Ageing Res. Rev.* 2014, 17, 25–33. [CrossRef] [PubMed]

85. Halper, B.; Hofmann, M.; Oesen, S.; Franzke, B.; Stuparits, P.; Vidotto, C.; Tschan, H.; Bachl, N.; Strasser, E.M.; Quittan, M.; et al. Influence of age and physical fitness on microRNA-21, TGF-beta and its receptors in leukocytes of healthy women. *Exerc. Immunol. Rev.* 2015, 21, 154–163. [PubMed]

86. Olivieri, F.; Bonafe, M.; Spazzafumo, L.; Gobbi, M.; Prattichizzo, F.; Recchioni, R.; Marcheselli, F.; Sala, L.L.; Galeazzi, R.; Rippo, M.R.; et al. Age- and glycemia-related microRNA-126-3p levels in plasma and endothelial cells. *Aging* 2014, 6, 771–787. [CrossRef] [PubMed]

87. Mushtaq, G.; Greig, N.H.; Anwar, F.; Zamzami, M.A.; Choudhry, H.; Shaik, M.M.; Tamargo, I.A.; Kamal, M.A. microRNAs as circulating biomarkers for Alzheimer’s disease and Parkinson’s disease. *Med. Chem.* 2016, 12, 217–225. [CrossRef] [PubMed]

88. Seeger, T.; Boon, R.A. MicroRNAs in cardiovascular ageing. *J. Physiol.* 2015, 594, 2085–2094. [CrossRef] [PubMed]

© 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).